Abstract
To asset the efficacy and safety of EPVL plus ESWL compared with ESWL alone for the treatment of simple upper urinary stones (<15mm). All patients with upper urinary stones (<15mm) were prospectively randomized into two groups. In treatment group, patients were assigned to immediate EPVL after ESWL, while in control group, ESWL alone was offered. All patients were reexamined at 1, 2, and 4weeks after ESWL. Stone size, stone location, stone-free rate (SFR), and complication rate were compared. 56 males and 20 females in treatment group were compared to 52 male and 25 females in control group (p=0.404). Median ages were 42.9±1.5years in treatment group and 42.7±1.3years in control group (p=0.943). Median stone size was 10.0±0.4mm (3-15mm) in treatment group and 10.4±0.4mm (4-15mm) in control group (p=0.622).The stone clearance rate in treatment and control group at 1week after ESWL was 51.3% (39/76) and 45.4% (35/77) (p>0.05), at 2weeks was 81.6% (62/76) and 64.9% (50/77) (p<0.05), and at 4weeks was 90.8% (69/76) and 75.3% (58/77) (p<0.05), respectively. EPVL is a noninvasive, effective, and safe adjunctive treatment which increases and accelerates upper urinary stones discharge after ESWL treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have